Nikita Shah, MD
Hematology & Oncology · Orlando, FLNPI 1265417505
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $342,949 of the $470,297 with a category attached, or 72.9%. 23 manufacturers reported payments, led by AstraZeneca at 41.7% of the total. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 519 payments — averaging $906.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$196K
- Novartis$109K
- Daiichi Sankyo Inc.$106K
- Seagen Inc.$31K
- Pfizer$9K
- Gilead$7K
- plus $12K from 17 others
Across 63 payments — averaging $3555.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$127K
- Daiichi Sankyo Inc.$60K
- Seagen Inc.$19K
- G1 Therapeutics, Inc.$10K
- Novartis$4K
- Macrogenics, Inc.$4K
What the payments were for
- Consulting fees$71,57815%
- Speaking & faculty fees$342,94973%
- Travel & lodging$38,5458%
- Food & beverage$11,4772%
- Education$680%
- Gifts$2,0980%
- Other$3,5821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 148 | $196,042 |
| Novartis | 175 | $108,675 |
| Daiichi Sankyo Inc. | 109 | $105,863 |
| Seagen Inc. | 31 | $31,229 |
| Pfizer | 7 | $9,038 |
| Gilead | 10 | $7,124 |
| Puma Biotechnology, Inc. | 4 | $4,300 |
| Athenex Pharmaceutical Division, LLC | 5 | $2,175 |
| Eisai Inc. | 1 | $1,785 |
| Hologic Sales And Service, LLC | 7 | $1,722 |
| Genentech USA, Inc. | 4 | $884 |
| Lantheus Medical Imaging, Inc. | 1 | $428 |
| Leica Microsystems Inc. | 1 | $285 |
| GSK | 4 | $167 |
| Mentor Worldwide LLC | 1 | $139 |
| Abbott | 1 | $139 |
| Dompe US, Inc. | 1 | $119 |
| Lilly USA, LLC | 3 | $51 |
| Merck | 2 | $45 |
| Stryker | 1 | $31 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$153,435
- KISQALI$83,572
- LYNPARZA$62,629
- PIQRAY$58,763
- TUKYSA$29,577
- DATROWAY$23,719
- Trodelvy$6,866
- IBRANCE$6,138
- Nerlynx$4,300
- Oral Paclitaxel$2,000
- Encequidar$2,000
- Halaven$1,785
- BTX$1,337
- Phesgo$825
- Aptima$673
- TALZENNA$400
- FETAL FIBRONECTIN ENZYME IMMUNOASSAY$288
- MENTOR MemoryGel Resterilizable Gel Sizer$139
- FREESTYLE LIBRE 3$139
- Oxervate$119
How this compares
$470,297 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 89 | $1,267,055 |
| IbrancePalbociclib | 67 | $981,728 |
| Kisqali Femara Co-PackRibociclib Succinate/Letrozole | 22 | $295,092 |
| VerzenioAbemaciclib | 12 | $185,802 |
| LapatinibLapatinib Ditosylate | 11 | $55,581 |
| EliquisApixaban | 26 | $14,998 |
| Anastrozole | 698 | $12,994 |
| Exemestane | 29 | $5,897 |
| Letrozole | 210 | $5,323 |
| Ondansetron Hcl | 60 | $1,862 |
| Prochlorperazine Maleate | 77 | $1,202 |
| Tamoxifen Citrate | 47 | $993 |
| Clonidine | 15 | $574 |
| Gabapentin | 29 | $539 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 41 | $529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $108,675 | $1,267,05589 claims |
| PfizerIbrance, Eliquis | $9,038 | $996,72693 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $51 | $186,03440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Orlando
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Daniel LandauOrlando$1.8M
- Shahram MoriOrlando$952K
- Sajeve ThomasOrlando$639K
- Martin DietrichRockledge$6.2M
- Edgardo SantosFort Lauderdale$2M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.